Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease
Issued Date
2022-09-01
Resource Type
ISSN
0125877X
eISSN
22288694
Scopus ID
2-s2.0-85136341711
Pubmed ID
31677617
Journal Title
Asian Pacific Journal of Allergy and Immunology
Volume
40
Issue
3
Start Page
247
End Page
253
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology Vol.40 No.3 (2022) , 247-253
Suggested Citation
Wongsa C., Sompornrattanaphan M., Tantilipikorn P., Thongngarm T. Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease. Asian Pacific Journal of Allergy and Immunology Vol.40 No.3 (2022) , 247-253. 253. doi:10.12932/ap-150619-0583 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/84918
Title
Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease
Author's Affiliation
Other Contributor(s)
Abstract
Background: Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD) is characterized by the triad of chronic rhinosinusitis with nasal polyp, asthma, and aspirin (ASA) or NSAID hypersensitivity. Previous study of NERD has rarely been reported in Asian population. Objectives: To investigate the clinical characteristics and outcomes of aspirin desensitization (ASAD) in Thai NERD patients. Methods: This retrospective chart review included patients with a suggestive history of NERD with or without ASAD from the Adult Allergy Clinic of Siriraj Hospital (Bangkok, Thailand) during January 2008 to December 2018. Results: Ten NERD patients were recruited. The median age of onset was 30 years. Comorbid atopic diseases were found in 4 patients. Asthma control level was step 3 of the Global Initiative for Asthma (GINA) guideline or greater in all patients. Five patients had reactions to more than one NSAIDs. Ibuprofen was the most common culprit agent. Reactions frequently involved the respiratory and cutaneous systems. Four patients underwent ASAD followed by ingestion of ASA 300-600 mg daily. One patient discontinued ASA after taking ASA 600 mg daily for 3 months due to severe gastrointestinal side effect. The remaining three patients successfully continued ASA 300 mg daily as maintenance to control sino-nasal inflammation and to prevent recurrence of nasal polyp. None of the 4 patients required sinus surgery revision. Conclusions: NERD is a difficult-to-treat disease with unique clinical characteristics. ASAD followed by a maintenance dose of ASA 300 mg daily was found to be effective and well-tolerated in most patients.